Group items tagged

The program provides support to nonprofits interested in making long-term improvements in their management, governance, and/or organizational capacity. Grants may be used for capacity-building activities that include but are not limited to strategic planning; financial management, including cash flow, budget development, and financial controls; program evaluation planning; communications and marketing, including website development, public relations, and the use of social media; resource development and fundraising; human resources, including professional development, succession planning, staffing structure, assessment, and retention; information systems management, including technology enhancements; board development, including assessment, recruitment, training, and structuring; and restructuring and relationship building with other nonprofit organizations aimed at strengthening service delivery, reducing costs, and sharing resources.

The overall goal of this FOA is to support the development of a collaborative research and resource network to synergize the expertise, skills, and resources of investigators within the geriatric emergency medicine and Alzheimer's disease and Alzheimer's disease-related dementias (AD/ADRD) research communities to identify and address research gaps towards optimizing recognition and emergency care of older adults with AD/ADRD. Support is provided for up to 2 years of planning/development (R61 phase) of a milestone-driven infrastructure including the initial identification of top-priority research gaps and the establishment of strategies to address them. Areas identified as needing additional evidence-based research include, but are not limited to, pre-emergency department (ED) strategies to avoid non-emergency ED visits, recognition of early cognitive impairment in the ED, strategies to optimize the ED environment and providers for patients with AD/ADRD, development of safe disposition criteria, and methods to minimize system fragmentation within and across health and social services.

Despite established associations between white matter lesions and cognitive impairment including dementia, little prospective information is available to define the characteristics of white matter lesions and associated comorbid clinical factors that cause further cognitive impairment, ultimately resulting in dementia. This initiative will support one large prospective clinical research study in the U.S. of patients engaged with the health care system because of incidental white matter lesions found on neuroimaging, who present with cognitive complaints, and who thus are at risk for cognitive decline. The goal will be to determine the volume and anatomical features that are both necessary and sufficient to cause cognitive impairment or dementia.

The Michigan Health Fund currently is accepting applications to its Healthy Aging program, which seeks to improve access to and the availability of integrated, comprehensive services for older adults and their caregivers. To that end, grants ranging from between $100,000 and $500,000 will be awarded in support of strategies and service delivery models focused on improving health outcomes for older adults and those who care for them. Grantmaking categories identified by the foundation include: Health Aging - The fund supports strategies designed to improve the health and well-being of older adults, including the development and piloting of new models aimed at better supporting older adults; the replication and expansion of evidence-based or promising models, the expansion of a current program to a new target population, or the replication of an existing program that does not yet exist in a local community and does not have a funding mechanism available; strategies that improve access to current or expanded services; projects that address the structural barriers and inefficiencies preventing various systems (e.g., education, health, social) from delivering care to older adults; and projects that address a significant issue area (e.g., social isolation) or various health disparities impacting older adults.

The purpose of the RERC program is to improve the effectiveness of services authorized under the Rehabilitation Act by conducting advanced engineering research on and development of innovative technologies that are designed to solve particular rehabilitation problems or to remove environmental barriers. RERCs also demonstrate and evaluate such technologies, facilitate service delivery system changes, stimulate the production and distribution of new technologies and equipment in the private sector, and provide training opportunities. Field-Initiated RERC on Technology to Enhance Independence and Community Living for People with Cognitive Impairments: In this area, NIDILRR seeks to fund research and development toward technologies that contribute to improved abilities of adults with cognitive impairment to perform daily activities of their choice in the home, community, or workplace.

Engaging in policy and advocacy is essential to building healthy communities. As communities work on age-friendly ideas that are relevant to them, the Foundation will support efforts that are inclusive, collaborative, address quality of life, and improve conditions for all across the lifespan. One aging framework we use is that of the World Health Organization Age-Friendly Cities initiative. Policy and Advocacy initiatives we will consider recognize the essential components that make up community wellbeing. They include: - Built environment - Transportation - Housing - Social and civic participation and inclusion - Employment - Communication and information - Community support and health services Proposals should include: * Community/civic engagement of diverse stakeholders in communities to mobilize and affect change * Participation among key stakeholders, including the voice of older adults, to support planning, policy and advocacy initiatives * Expanded access to programs and services as well as system change/improvement

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) invites applications to evaluate the cumulative and progressive effects on brain structure and cognitive/behavioral function of combined HIV infection and alcohol abuse on older patients cohorts.

The Blueprint Neurotherapeutics Network (BPN) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee Institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.

The Blueprint Neurotherapeutics Network (BPN) encourages applications from small businesses seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN are responsible for conducting all studies that involve disease- or target-specific assays, models, and other research tools and receive funding for all activities to be conducted in their own laboratories. In addition, applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis including under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize promising hit compounds through medicinal chemistry, or at the Development stage, to advance a development candidate through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Projects that enter at the Discovery stage and meet their milestones may continue on through Development. BPN awardee institutions retain their assignment of IP rights and gain assignment of IP rights from the BPN contractors (and thereby control the patent prosecution and licensing negotiations) for drug candidates developed in this program.